EGFR and neoplasm: It has been recognized that patients with RM‐NPC are likely to harbor platinum‐resistant tumor clones, which may be partially due to the activation of the EGFR signaling pathway.21, 22 Therefore, it is rational that blocking the EGFR pathway could resensitize these tumor clones to chemotherapy and delay disease progression.6, 8, 9 Moreover, Chan et al17 conducted a phase II trial, which included 60 RM‐NPC patients who had been heavily treated with platinum‐based chemotherapy for recurrent or metastatic disease.